# EDGAR Filing Document

**Accession Number:** 0001627281
**File Stem:** 0001193125-23-027693
**Filing Date:** 2023-2
**Character Count:** 9720
**Document Hash:** 9410c97bcfd2d33b3fae98797dbc7a8a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-027693.hdr.sgml**: 20230208

**ACCESSION NUMBER**: 0001193125-23-027693

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230208

**FILED AS OF DATE**: 20230208

**DATE AS OF CHANGE**: 20230208

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cellectis S.A.
- **CENTRAL INDEX KEY:** 0001627281
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36891
- **FILM NUMBER:** 23597169

**BUSINESS ADDRESS:**
- **STREET 1:** 8 RUE DE LA CROIX JARRY
- **CITY:** PARIS, LLE-DE-FRANCE
- **STATE:** I0
- **ZIP:** 75013
- **BUSINESS PHONE:** 33181691600

**MAIL ADDRESS:**
- **STREET 1:** 8 RUE DE LA CROIX JARRY
- **CITY:** PARIS, LLE-DE-FRANCE
- **STATE:** I0
- **ZIP:** 75013

------

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM 6-K** 

------

**Report of Foreign Private Issuer** 

**Pursuant to Rule 13a-16 or 15d-16** 

**of the Securities Exchange Act of 1934** 

**Date of Report: February 8, 2023** 

**Commission File Number: 001-36891** 

------

## Cellectis S.A.
**(Exact Name of registrant as specified in its charter)** 

------

**8, rue de la Croix Jarry** 

**75013 Paris, France** 

**+33 1 81 69 16 00** 

**(Address of principal executive office)** 

------

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

------

**Cellectis S.A.** 

This Report on Form 6-K shall be deemed to be incorporated by reference in the registration statement of Cellectis S.A. (the "Company") on Form F-3 (No. 333-265826), to the extent not superseded by documents or reports subsequently filed.

**Information contained in this Report** 

The Company previously announced its offering of (i) 8,800,000 ordinary shares of the Company, nominal value €0.05 per share (the "Firm Shares"), to be delivered in the form of an aggregate of 8,800,000 American Depositary Shares (the "ADSs"), each ADS representing the right to receive one ordinary share of the Company, and (ii) at the option of the underwriters, up to an additional 1,320,000 ordinary shares of the Company (the "Option Shares") to be delivered in the form of an aggregate of 1,320,000 ADSs, in each case at a public offering price of $2.50 per ADS (the "Offering"). On February 7, 2023, the Company announced the exercise by the underwriters, Jefferies LLC and Barclays Capital Inc., of their option to purchase an additional 1,107,800 ordinary shares of the Company to be delivered in the form of 1,107,800 ADSs.

The legal opinion of Jones Day relating to the ordinary shares in the Offering is filed as Exhibit 5.1 to this Report on Form 6-K and incorporated by reference herein and a consent relating to the incorporation of such opinion is filed as Exhibit 23.1 by reference to its inclusion within Exhibit 5.1 and incorporated by reference herein.

This Report on Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy the securities discussed herein.

------

**EXHIBITS** 

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 5.1 | [Opinion of Jones Day, French counsel to the registrant.](d382695dex51.htm) |
| 23.1 | [Consent of Jones Day (included in Exhibit 5.1).](d382695dex51.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CELLECTIS SA** | **CELLECTIS SA** |
| Date: February 8, 2023 | By: | /s/ André Choulika |
|  |  | André Choulika |
|  |  | *Chief Executive Officer* |

---

## Exhibit 5.1

**Exhibit 5.1** 

JONES DAY

*PARTNERSHIP CONSTITUEE SELON LE DROIT DE L'OHIO, USA* 

*AVOCATS AU BARREAU DE PARIS* 

*2, RUE SAINT-FLORENTIN • 75001 PARIS* 

*TELEPHONE: (0)1.56.59.39.39 • FACSIMILE: (0)1.56.59.39.38 • TOQUE J 001* 

*WWW.JONESDAY.COM* 

February 8, 2023

Cellectis S.A.

8, rue de la Croix Jarry

75013 Paris, France

Re: 10,120,000 ordinary shares in the form of American depositary shares issued by Cellectis SA

Ladies and Gentlemen:

We are acting as special French counsel for Cellectis S.A. (the "Company"), a French société anonyme, in connection with the issuance and sale by the Company of up to 10,120,000 ordinary shares, par value €0.05 (the "New Shares") to be delivered in the form of an aggregate of 10,120,000 American depositary shares (the "ADSs"), each ADS representing one ordinary share of the Company, comprising: (i) 8,800,000 ordinary shares, par value €0.05 (the "Firm Shares") delivered in the form of an aggregate of 8,800,000 ADSs and (ii) up to 1,320,000 ordinary shares, par value €0.05 (the "Option Shares") to be delivered in the form of an aggregate of 1,320,000 ADSs.

The New Shares are included in the shelf registration statement on Form F-3 (No. 333-265826) filed by the Company with the Securities and Exchange Commission ("SEC") on June 24, 2022, as amended, in the form in which it became effective on July 7, 2022 (the "Form F-3"), including the final prospectus supplement dated as of February 2, 2023, and filed by the Company pursuant to Rule 424(b) under the Securities Act on February 3, 2023, relating to the New Shares underlying the ADSs (the "Prospectus Supplement" and, together with the Form F-3, the "Prospectus"). The issuance and subscription of the New Shares is pursuant to the underwriting agreement (the "Underwriting Agreement") entered into by and among the Company on the one hand and Jefferies LLC and Barclays Capital Inc., acting as the representative of the several underwriters named in the Underwriting Agreement on the other hand, substantially in the form filed by the Company as exhibit 1.1 to a Current Report on Form 6-K filed on February 7, 2023.

In connection with the opinions expressed herein, we have examined such documents, records and matters of law as we have deemed relevant or necessary for purposes of such opinions. Based on the foregoing, and subject to the further limitations, qualifications and assumptions set forth herein, we are of the opinion that, as of the date hereof:

1. The issuance of the New Shares has been duly authorized;

------

JONES DAY

Cellectis S.A.

2. The New Shares, when issued and delivered pursuant to the Underwriting Agreement against full payment of their subscription price as provided in the Underwriting Agreement, as shall be acknowledged by the certificate of the depository (certificat du dépositaire) to be delivered by Société Générale Securities Services, will be validly issued and fully paid and non-assessable.

The term "non-assessable", which has no recognized meaning in French law, for the purposes of this opinion means that no present or future holder of ordinary shares will be subject to personal liability, by reason of being such a holder, for additional payments or calls for further funds by the Company or any other person after the issuance of the ordinary shares.

In rendering the foregoing opinion, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals and the conformity to originals of all documents submitted to us as certified or reproduced copies and we have also assumed that (i) the Form F-3, and any amendments thereto, will be effective at the time of issuance of the New Shares; (ii) the resolutions authorizing the Company to issue, offer and sell the New Shares as adopted by the extraordinary shareholders' meeting and/or the board of directors of the Company, as applicable, are accurately reflected in the minutes of such meetings provided to us; and (iii) all New Shares will be issued in compliance with applicable securities and corporate law.

The opinions expressed herein are limited by bankruptcy, insolvency, reorganization, fraudulent transfer and fraudulent conveyance, voidable preference, moratorium or other similar laws and related regulations and judicial doctrines from time to time in effect relating to or affecting creditor's rights generally, and by public policy and public order considerations.

As to facts material to the opinions and assumptions expressed herein, we have relied upon written statements and representations of officers and other representatives of the Company. We are members of the Paris bar and this opinion is limited to the laws of the Republic of France as currently in effect. This opinion is subject to the sovereign power of the French courts to interpret agreements and assess the facts and circumstances of any adjudication. This opinion is given on the basis that it is to be governed by, and construed in accordance with, the laws of the Republic of France.

We hereby consent to the filing of this opinion as Exhibit 5.1 to the Current Report on Form 6-K filed on the date hereof by the Company and incorporated by reference into the Form F-3 and to the reference to Jones Day under the caption "Legal Matters" in each of the prospectus and the Prospectus Supplement constituting a part of such Registration Statement. In giving such consent, we do not thereby admit that we are included in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the SEC promulgated thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Jones Day |

---